Resolvin E1 inhibits neuropathic pain and spinal cord microglial activation following peripheral nerve injury.

Published

Journal Article

Accumulating evidence indicates that activation of spinal cord microglia plays an important role in the genesis of neuropathic pain. Resolvin E1 (E1) is derived from omega-3 polyunsaturated fatty acid and exhibits potent anti-inflammatory, pro-resolution, and anti-nociceptive effects. We further examined whether RvE1 could reduce neuropathic pain and modulate spinal cord microglial activation. Intrathecal pre-treatment of RvE1 (100 ng) daily for 3 days partially prevented the development of nerve injury-induced mechanical allodynia and up-regulation of IBA-1 (microglial marker) and TNF-α in the spinal cord dorsal horn. Furthermore, intrathecal post-treatment of RvE1 (100 ng), 3 weeks after nerve injury, transiently reduced mechanical allodynia and heat hyperalgesia. Finally, RvE1 blocked lipopolisaccharide-induced microgliosis and TNF-α release in primary micoglial cultures. Our data suggest that RvE1 may attenuate neuropathic pain via inhibiting microglial signaling. Targeting the anti-inflammatory and pro-resolution lipid mediators may offer new options for preventing and treating neuropathic pain.

Full Text

Duke Authors

Cited Authors

  • Xu, Z-Z; Berta, T; Ji, R-R

Published Date

  • March 2013

Published In

Volume / Issue

  • 8 / 1

Start / End Page

  • 37 - 41

PubMed ID

  • 22878925

Pubmed Central ID

  • 22878925

Electronic International Standard Serial Number (EISSN)

  • 1557-1904

International Standard Serial Number (ISSN)

  • 1557-1890

Digital Object Identifier (DOI)

  • 10.1007/s11481-012-9394-8

Language

  • eng